FGFR3 and urinary bladder cancer: A phase I trial using an intermittent dosing schedule of the pan‐FGFR3 inhibitor JNJ‐42756493 on patients with advanced bladder cancer with confirmed FGFR alterations 28 and a case report for phase I AZD4547, a selective FGFR inhibitor targeting FGFR1/2/3 29, also showed promising results.